The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers

• Váldodahkkit: Stefan J. Jodl (Dahkki), Wouter tenVoorde (Dahkki), Stefan Klein (Dahkki), Andrea Wagenfeld (Dahkki), Frank S. Zollmann (Dahkki), Maximilian Feldmüller (Dahkki), Naomi B. Klarenbeek (Dahkki), Digna T. deBruin (Dahkki), Manon A. A. Jansen (Dahkki), Robert Rissmann (Dahkki), Beate Rohde (Dahkki), Matthijs Moerland (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2024-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract This study evaluated and characterized the pharmacological activity of the orally administered interleukin‐1 receptor‐associated kinase 4 (IRAK4) inhibitors BAY1834845 (zabedosertib) and BAY1830839 in healthy male volunteers. Participants received one of either IRAK4 inhibitors or a control...